Stem is trading 12% down at $2.50; no confirmed company announcement or specific catalyst has been identified for the October 28 decline. - The October 26 strategic-alternatives review, potentially including a sale, merger, or other options, remains unresolved. - There is no timetable or assurance of a transaction; the review is prior context, not a confirmed explanation for the decline. - The broader market is mixed in the supplied context and does not clearly explain the sharp move; available evidence does not establish a cause.